Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

Journal of Clinical Oncology

Volumn 29, Issue 29, 2011, Pages 3877-3884

  Eiermann, Wolfgang ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Pienkowski, Tadeusz ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Crown, John ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Sadeghi, Saeed ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Martin, Miguel ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Chan, Arlene ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Saleh, Mansoor ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Sehdev, Sandeep ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Provencher, Louise ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Semiglazov, Vladimir ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Press, Michael ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Sauter, Guido ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Lindsay, Mary Ann ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Riva, Alessandro ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Buyse, Marc ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Drevot, Philippe ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Taupin, Henry ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}   Mackey, John R ^{a,b,c,d,e,f,g,h,i,j,k,l,m,n,o}  

^a University Women's Hospital   (Germany)

^b Breast Cancer Clinic   (Poland)

^c All Ireland Co Operative Oncology Research Group   (Ireland)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e Mount Medical Center   (Australia)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g University of Queensland   (Canada)

^h LAVAL UNIVERSITY   (Canada)

ⁱ N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l UNIVERSITY OF BASEL   (Switzerland)

^m Cancer International Research Group   (France)

ⁿ International Drug Development Institute Statistics   (Belgium)

^o CROSS CANCER INSTITUTE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADD ON THERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; FOLLOW UP; HUMAN; INCIDENCE; LEUKEMIA; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SYNCOPE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; YOUNG ADULT;

EID: 80053988319     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.28.5437     Document Type: Article

References (19)

1. Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 17:2341-2354, 1999 (Pubitemid 29368232)
2. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 21:588-592, 2003 (Pubitemid 46621890)
3. Sparano JA, O'Neill A, Schaefer PL, et al: Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 18:2369-2377, 2000 (Pubitemid 30415823)
4. Smith RE, Anderson SJ, Brown A, et al: Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: Results from NSABP trial BP-58. Clin Breast Cancer 3:333-340, 2002 (Pubitemid 36124470)
5. Mackey J, Paterson A, Dirix L, et al: Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy for patients with metastatic breast cancer. J Clin Oncol 21:25a, 2002 (suppl;abstr 137)
6. Miller KD, McCaskill-Stevens W, Sisk J, et al: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033-3037, 1999 (Pubitemid 29470630)
7. von Minckwitz G, Costa SD, Eiermann W, et al: Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 17:1999-2005, 1999
8. von Minckwitz G, Costa SD, Raab G, et al: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. J Clin Oncol 19:3506-3515, 2001 (Pubitemid 32730088)
9. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005 (Pubitemid 40740554)
10. Eiermann W, Pienkowski T, Crown J, et al: Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC3T) in HER-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. Presented at the 28th San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2005 (abstr 1069)
11. Martín M, Lluch A, Seguí MA, et al: Toxicity and health related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol 17:1205-1212, 2006 (Pubitemid 44288210)
12. Smith T, Khatcheressian J, Lyman G, et al: 2006 Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
13. Moreira A, Lobato R, Morais J, et al: Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemother Pharmacol 48(4):333-337, 2001 (Pubitemid 32835359)
14. Swain SM, Jeong J-H, Geyer CE, et al: NSABP B-30: Definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 11-14, 2008 (abstr 75)
15. Brain EG, Deblet M, Eymard J-C, et al: Final results of the RAPP-01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high-risk node-negative and limited node positive (≥ 3) breast cancer patients. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 11-14, 2008 (abstr 4101)
16. Goldstein LJ, O'Neill A, Sparano JA, et al: Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 26:4092-4099, 2008
17. Coudert B, Campone M, Spielmann M, et al: Benefit of the sequential administration of docetaxel after standard fec regimen for node-positive breast cancer: Long-Term Follow-up results of the FNCLCC-PACS 01 trial. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 11-14, 2009 (abstr 603)
18. Nitz U, Huober J, Lisboa B, et al: Superiority of sequential docetaxel over standard FE100C in patients with intermediate risk breast cancer: Survival results of the randomized intergroup phase III trial EC-Doc. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 11-14, 2008 (abstr 78)
19. Francis P, Crown J, Di Leo A, et al: Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 100:121-133, 2008 (Pubitemid 351480565)